Cargando…
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici O...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538824/ https://www.ncbi.nlm.nih.gov/pubmed/34696233 http://dx.doi.org/10.3390/vaccines9101125 |
_version_ | 1784588599255105536 |
---|---|
author | Campo, Flaminia Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Conti, Laura De Virgilio, Armando De Marco, Federico Di Noia, Vincenzo Di Domenico, Enea Gino Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Sperandio, Eleonora Rosati, Valentina Cognetti, Francesco Morrone, Aldo Ciliberto, Gennaro Pellini, Raul |
author_facet | Campo, Flaminia Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Conti, Laura De Virgilio, Armando De Marco, Federico Di Noia, Vincenzo Di Domenico, Enea Gino Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Sperandio, Eleonora Rosati, Valentina Cognetti, Francesco Morrone, Aldo Ciliberto, Gennaro Pellini, Raul |
author_sort | Campo, Flaminia |
collection | PubMed |
description | Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Results: Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53–339.52) with a significant increase compared to baseline (p < 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Conclusions: Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts. |
format | Online Article Text |
id | pubmed-8538824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85388242021-10-24 Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers Campo, Flaminia Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Conti, Laura De Virgilio, Armando De Marco, Federico Di Noia, Vincenzo Di Domenico, Enea Gino Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Sperandio, Eleonora Rosati, Valentina Cognetti, Francesco Morrone, Aldo Ciliberto, Gennaro Pellini, Raul Vaccines (Basel) Brief Report Background: We present immunogenicity data 6 months after the first dose of BNT162b2 in correlation with age, gender, BMI, comorbidities and previous SARS-CoV-2 infection. Methods: An immunogenicity evaluation was carried out among health care workers (HCW) vaccinated at the Istituti Fisioterapici Ospitalieri (IFO). All HCW were asked to be vaccine by the national vaccine campaign at the beginning of 2021. Serum samples were collected on day 1 just prior to the first dose of the vaccine and on day 21 just prior to the second vaccination dose. Thereafter sera samples were collected 28, 49, 84 and 168 days after the first dose of BNT162b2. Quantitative measurement of IgG antibodies against S1/S2 antigens of SARS-CoV-2 was performed with a commercial chemiluminescent immunoassay. Results: Two hundred seventy-four HWCs were analyzed, 175 women (63.9%) and 99 men (36.1%). The maximum antibody geometric mean concentration (AbGMC) was reached at T2 (299.89 AU/mL; 95% CI: 263.53–339.52) with a significant increase compared to baseline (p < 0.0001). Thereafter, a progressive decrease was observed. At T5, a median decrease of 59.6% in COVID-19 negative, and of 67.8% in COVID-19 positive individuals were identified with respect to the highest antibody response. At T1, age and previous COVID-19 were associated with differences in antibody response, while at T2 and T3 differences in immune response were associated with age, gender and previous COVID-19. At T4 and T5, only COVID-19 positive participants demonstrated a greater antibody response, whereas no other variables seemed to influence antibody levels. Conclusions: Overall our study clearly shows antibody persistence at 6 months, albeit with a certain decline. Thus, the use of this vaccine in addressing the COVID-19 pandemic is supported by our results that in turn open debate about the need for further boosts. MDPI 2021-10-03 /pmc/articles/PMC8538824/ /pubmed/34696233 http://dx.doi.org/10.3390/vaccines9101125 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Campo, Flaminia Venuti, Aldo Pimpinelli, Fulvia Abril, Elva Blandino, Giovanni Conti, Laura De Virgilio, Armando De Marco, Federico Di Noia, Vincenzo Di Domenico, Enea Gino Di Martino, Simona Ensoli, Fabrizio Giannarelli, Diana Mandoj, Chiara Mazzola, Francesco Moretto, Silvia Petruzzi, Gerardo Petrone, Fabrizio Pichi, Barbara Pontone, Martina Vidiri, Antonello Vujovic, Branka Piaggio, Giulia Sperandio, Eleonora Rosati, Valentina Cognetti, Francesco Morrone, Aldo Ciliberto, Gennaro Pellini, Raul Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers |
title | Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers |
title_full | Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers |
title_fullStr | Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers |
title_full_unstemmed | Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers |
title_short | Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers |
title_sort | antibody persistence 6 months post-vaccination with bnt162b2 among health care workers |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538824/ https://www.ncbi.nlm.nih.gov/pubmed/34696233 http://dx.doi.org/10.3390/vaccines9101125 |
work_keys_str_mv | AT campoflaminia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT venutialdo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT pimpinellifulvia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT abrilelva antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT blandinogiovanni antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT contilaura antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT devirgilioarmando antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT demarcofederico antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT dinoiavincenzo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT didomenicoeneagino antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT dimartinosimona antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT ensolifabrizio antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT giannarellidiana antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT mandojchiara antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT mazzolafrancesco antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT morettosilvia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT petruzzigerardo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT petronefabrizio antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT pichibarbara antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT pontonemartina antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT vidiriantonello antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT vujovicbranka antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT piaggiogiulia antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT sperandioeleonora antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT rosativalentina antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT cognettifrancesco antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT morronealdo antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT cilibertogennaro antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers AT pelliniraul antibodypersistence6monthspostvaccinationwithbnt162b2amonghealthcareworkers |